ZHENGDANCHEM(SZ:300641) Chang Jiang Shang Bao·2025-04-17 00:18Core Insights - Zhengdan Co., Ltd. reported exceptional financial results for 2024, with a revenue of 3.48 billion yuan, a year-on-year increase of 126.31%, and a net profit attributable to shareholders of 1.19 billion yuan, reflecting a staggering growth of approximately 11,949.30% [2][3][5] Financial Performance - The company achieved a net profit of 1.19 billion yuan and a net profit excluding non-recurring items of 1.18 billion yuan, with year-on-year growth rates of about 11,949.30% and 25,313.81% respectively [3][4] - Quarterly revenue for 2024 was reported as follows: Q1: 518 million yuan, Q2: 864 million yuan, Q3: 1.21 billion yuan, Q4: 884 million yuan, with year-on-year growth rates of 28.80%, 155.08%, 214.25%, and 115.40% respectively [3][4] - The operating cash flow net amount reached 892 million yuan, marking a year-on-year increase of 431.03% [7] Market Dynamics - The significant growth in performance is attributed to the permanent closure of TMA production lines by U.S. manufacturers, leading to a notable increase in overseas demand for Chinese TMA [5][6] - The sales volume and price of TMA, the company's main product, saw substantial increases compared to the previous year, contributing to the overall revenue growth [5][6] Operational Efficiency - The company has successfully enhanced its production capacity and efficiency, with a significant increase in the utilization rates of TMA and TOTM products, leading to reduced marginal costs and improved profitability [5][6] - The comprehensive gross margin and net margin for 2024 were reported at 41.49% and 34.19%, respectively, reflecting increases of 37.64 percentage points and 33.55 percentage points year-on-year [6] Strategic Initiatives - Zhengdan Co., Ltd. is expanding its production capabilities, with plans to invest 350 million yuan in a green upgrade project for TMA production, aimed at addressing current capacity shortages and filling market gaps [6] - The company has also initiated a project for high molecular specialty resin monomers, further diversifying its product offerings [6] Financial Health - As of the end of 2024, the company's asset-liability ratio was 8.98%, a significant decrease of 21.58 percentage points from the previous year, indicating strong financial stability [7] - The company proposed a cash dividend of 368 million yuan, with a dividend payout ratio of 30.92%, reflecting a cautious approach to profit distribution despite strong earnings [7]